Last updated on July 2018

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot and Dose-Ranging Study of GDC-0853 in Patients With Refractory Chronic Spontaneous Urticaria (CSU)


Brief description of study

The purpose this study is to evaluate the efficacy, safety, and pharmacokinetics of GDC-0853 compared with placebo in participants with Chronic Spontaneous Urticaria (CSU) refractory to anti-histamines.

Clinical Study Identifier: TX208439

Find a site near you

Start Over

University of South Florida-Morsani College of Medicine

13801 Bruce B Downs Blvd. Suite 505 Tampa, FL USA
  Connect »